Proteome Sciences has reported positive results from the in-vivo study of its CK1D inhibitor programme in Alzheimer’s disease.

The in-vivo study demonstrated that CK1D inhibitors improved cognition in Alzheimer’s model.

Data demonstrated the efficacy of the company’s lead compounds for CK1D and provided important in-vivo proof of principle.

Proteome Sciences chief operating officer Dr Ian Pike said the results further validate the company’s proteomic approach in discovery of new drug targets in challenging diseases.

"By diligently following the tau hypothesis of Alzheimer’s disease we have been able to develop exciting new therapeutic strategies that are increasingly recognised by the scientific community as important components of the fight to halt Alzheimer’s disease progression," Pike said.

"We believe that inhibiting CK1D will be an important component in treatment of AD and we will concentrate on rapidly developing these assets."

The company previously reported that CK1D inhibitors block tau phosphorylation in cell lines in an in-vitro study.

The next phase is anticipated to begin in January 2013 to commence and complete a comprehensive assessment of biological indicators and drug levels in a range of tissues.

Proteome Sciences CEO Christopher Pearce said the company has achieved the goal of delivering in-vivo proof of principle for CK1D in Alzheimer’s disease.

"These results are most timely as major pharmaceutical companies and academia have increasingly been switching attention to the importance of tau tangles in combination with amyloid aggregation in Alzheimer’s," Pearce said.

"In light of UK Government’s recent commitment to fully fund NHS access to novel treatments for AD we believe there is significant potential for CK1D inhibitors to positively affect the lives of sufferers and their carers."